Clindamycin Phosphate and Benzoyl Peroxide

×

Overview

What is Clindamycin Phosphate and Benzoyl Peroxide?

Clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% is a fixed combination product with two active ingredients in a white to slightly yellow, opaque, aqueous gel formulation.

Clindamycin phosphate is a water soluble ester of the semi-synthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin.

Clindamycin phosphate is CHClNOPS. The structural formula for clindamycin phosphate is represented below:

Clindamycin phosphate has a molecular weight of 504.97 and its chemical name is methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl--4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L--α-D--octopyranoside 2-(dihydrogen phosphate).

Benzoyl peroxide is CHO. It has the following structural formula:

Benzoyl peroxide has a molecular weight of 242.23.

Each gram of clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% contains 10 mg (1%) clindamycin, as clindamycin phosphate, and 50 mg (5%) benzoyl peroxide in a base consisting of carbomer homopolymer (type C), dimethicone, disodium lauryl sulfosuccinate, edetate disodium, glycerin, methylparaben, poloxamer 182, purified water, silicon dioxide, and sodium hydroxide.

What does Clindamycin Phosphate and Benzoyl Peroxide look like?

What are the available doses of Clindamycin Phosphate and Benzoyl Peroxide?

Gel, 1.2%/5%: Each gram of clindamycin phosphate and benzoyl peroxide gel contains 12 mg clindamycin phosphate (equivalent to 10 mg of clindamycin) and 50 mg benzoyl peroxide. ()

What should I talk to my health care provider before I take Clindamycin Phosphate and Benzoyl Peroxide?

How should I use Clindamycin Phosphate and Benzoyl Peroxide?

Clindamycin phosphate and benzoyl peroxide gel, 1.2%/5% is indicated for the topical treatment of inflammatory acne vulgaris in patients 12 years and older.

Apply a thin layer of clindamycin phosphate and benzoyl peroxide gel to the face once daily, in the evening or as directed by the physician. The skin should be gently washed, rinsed with warm water, and patted dry before applying clindamycin phosphate and benzoyl peroxide gel. Avoid the eyes, mouth, lips, mucous membranes, or areas of broken skin.

Clindamycin phosphate and benzoyl peroxide gel is not for oral, ophthalmic, or intravaginal use.

What interacts with Clindamycin Phosphate and Benzoyl Peroxide?

Sorry No Records found

What are the warnings of Clindamycin Phosphate and Benzoyl Peroxide?

Sorry No Records found

What are the precautions of Clindamycin Phosphate and Benzoyl Peroxide?

Sorry No Records found

What are the side effects of Clindamycin Phosphate and Benzoyl Peroxide?

Sorry No records found

What should I look out for while using Clindamycin Phosphate and Benzoyl Peroxide?

Patients who have demonstrated hypersensitivity (e.g., anaphylaxis) to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. ()

Patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis (including pseudomembranous colitis). ()

What might happen if I take too much Clindamycin Phosphate and Benzoyl Peroxide?

Sorry No Records found

How should I store and handle Clindamycin Phosphate and Benzoyl Peroxide?

Pharmacist:Medroxyprogesterone Acetate Tablets USP are available as:Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.TEVA PHARMACEUTICALS USA, INC.North Wales, PA 19454Rev. A 5/2015Medroxyprogesterone Acetate Tablets USP are available as:Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.TEVA PHARMACEUTICALS USA, INC.North Wales, PA 19454Rev. A 5/2015Medroxyprogesterone Acetate Tablets USP are available as:Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.TEVA PHARMACEUTICALS USA, INC.North Wales, PA 19454Rev. A 5/2015Medroxyprogesterone Acetate Tablets USP are available as:Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.TEVA PHARMACEUTICALS USA, INC.North Wales, PA 19454Rev. A 5/2015Medroxyprogesterone Acetate Tablets USP are available as:Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.TEVA PHARMACEUTICALS USA, INC.North Wales, PA 19454Rev. A 5/2015Medroxyprogesterone Acetate Tablets USP are available as:Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.TEVA PHARMACEUTICALS USA, INC.North Wales, PA 19454Rev. A 5/2015Medroxyprogesterone Acetate Tablets USP are available as:Dispense in a tight, light-resistant container as defined in the USP, with a child-resistant closure (as required).Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.TEVA PHARMACEUTICALS USA, INC.North Wales, PA 19454Rev. A 5/2015

×

Clinical Information

Chemical Structure

No Image found

Clinical Pharmacology

Non-Clinical Toxicology

Patients who have demonstrated hypersensitivity (e.g., anaphylaxis) to clindamycin, benzoyl peroxide, any components of the formulation, or lincomycin. ()

Patients with a history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis (including pseudomembranous colitis). ()

Known drug interactions include barbiturates, tranquilizers, and alcohol. Diphenoxylate hydrochloride and atropine sulfate may interact with MAO inhibitors (see ).

In studies with male rats, diphenoxylate hydrochloride was found to inhibit the hepatic microsomal enzyme system at a dose of 2 mg/kg/day. Therefore, diphenoxylate has the potential to prolong the biological half-lives of drugs for which the rate of elimination is dependent on the microsomal drug metabolizing enzyme system.

Systemic absorption of clindamycin has been demonstrated following topical use of clindamycin.

Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of topical and systemic clindamycin. If significant diarrhea occurs, clindamycin phosphate and benzoyl peroxide gel should be discontinued.

Severe colitis has occurred following oral and parenteral administration of clindamycin with an onset of up to several weeks following cessation of therapy. Antiperistaltic agents such as opiates and diphenoxylate with atropine may prolong and/or worsen severe colitis. Severe colitis may result in death.

Studies indicate a toxin(s) produced by Clostridia is one primary cause of antibiotic-associated colitis. The colitis is usually characterized by severe persistent diarrhea and severe abdominal cramps and may be associated with the passage of blood and mucus. Stool cultures for and stool assay for toxin may be helpful diagnostically.

The following adverse reaction is described in more detail in the section of the label:

×

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

×

Review

×

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72

×

Tips

×

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).

Disclaimer: